Education
About Us
Working with TipRanks
Follow Us
Neurocrine (NBIX)
NASDAQ:NBIX
NBIX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$84.23 - $154.61
Previous CloseN/A
Volume209.65K
Average Volume (3M)918.06K
Market Cap
$13.85B
Enterprise Value$12.21B
Total Cash (Recent Filing)$975.60M
Total Debt (Recent Filing)$439.10M
Price to Earnings (P/E)41.2
Beta0.63
Next Earnings
Nov 04, 2025EPS Estimate
1.56Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.06
Shares Outstanding99,181,510
10 Day Avg. Volume621,027
30 Day Avg. Volume918,060
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.88
Enterprise Value/Revenue4.86
Enterprise Value/Gross Profit4.94
Enterprise Value/Ebitda21.84
Forecast
1Y Price Target
$166.13Price Target Upside17.06% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering25
Bulls Say, Bears Say
Bulls Say
Financial PerformanceNeurocrine posted a breakout quarter for Crenessity, generating $53M in sales, significantly surpassing consensus expectations.
Product LaunchThe Crenessity launch has been solid beating both the company's and investor expectations, and management is pleased with the performance so far.
Bears Say
Pricing PressureManagement expects a 5% hit to the average selling price driven by increased contracting for Medicare formulary coverage.
Revenue GuidanceNeurocrine lowered its FY25 Ingrezza guidance by $50M at the top end, suggesting that Ingrezza's revenue growth in the VMAT2 market may be hampered by continued Austedo growth.
Neurocrine News
NBIX FAQ
What was Neurocrine’s price range in the past 12 months?
Neurocrine lowest stock price was $84.23 and its highest was $154.61 in the past 12 months.
What is Neurocrine’s market cap?
Neurocrine’s market cap is $13.85B.
When is Neurocrine’s upcoming earnings report date?
Neurocrine’s upcoming earnings report date is Nov 04, 2025 which is in 61 days.
How were Neurocrine’s earnings last quarter?
Neurocrine released its earnings results on Jul 30, 2025. The company reported $1.06 earnings per share for the quarter, beating the consensus estimate of $0.965 by $0.095.
Is Neurocrine overvalued?
According to Wall Street analysts Neurocrine’s price is currently Undervalued.
Does Neurocrine pay dividends?
Neurocrine does not currently pay dividends.
What is Neurocrine’s EPS estimate?
Neurocrine’s EPS estimate is 1.56.
How many shares outstanding does Neurocrine have?
Neurocrine has 99,181,510 shares outstanding.
What happened to Neurocrine’s price movement after its last earnings report?
Neurocrine reported an EPS of $1.06 in its last earnings report, beating expectations of $0.965. Following the earnings report the stock price went down -6.237%.
Which hedge fund is a major shareholder of Neurocrine?
Currently, no hedge funds are holding shares in NBIX
Neurocrine Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$166.13 (17.06% Upside)
$166.13 (17.06% Upside)
Blogger Sentiment
Bullish
NBIX Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 663.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 0.9%
Last 30 Days ▲ 0.4%
Last 30 Days ▲ 0.4%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
11.69%
12-Months-Change
Fundamentals
Return on Equity
13.39%
Trailing 12-Months
Asset Growth
17.69%
Trailing 12-Months
Company Description
Neurocrine
Neurocrine Biosciences, Inc. (NBIX) is a biopharmaceutical company focused on discovering, developing, and commercializing innovative therapies for neurological and endocrine diseases. Founded in 1992 and headquartered in San Diego, California, Neurocrine operates in the biopharmaceutical sector, with a focus on conditions such as movement disorders, psychiatric disorders, and endocrine diseases. The company’s core products include Ingrezza (valbenazine), which is approved for the treatment of tardive dyskinesia, and Ongentys (opicapone), used in Parkinson's disease management.
NBIX Company Deck
NBIX Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong financial performance and successful product launches, particularly with CRENESSITY and INGREZZA, alongside robust pipeline development. However, there are notable challenges such as the failure of the valbenazine study to meet its primary endpoint and pricing pressures on INGREZZA. Despite these challenges, the overall sentiment reflects confidence in continued growth and strategic investments.View all NBIX earnings summariesNBIX Stock 12 Month Forecast
Average Price Target
$166.13
▲(17.06% Upside)
Technical Analysis
Dr Reddy's Laboratories
―
Viatris
―
Pacira Pharmaceuticals
―
Teva Pharmaceutical
―
Amphastar Pharmaceuticals
―
Ownership Overview
1.10% Insiders
28.89% Mutual Funds
25.36% Other Institutional Investors
17.15% Public Companies and
Individual Investors